EA201992434A1 - Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия - Google Patents

Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия

Info

Publication number
EA201992434A1
EA201992434A1 EA201992434A EA201992434A EA201992434A1 EA 201992434 A1 EA201992434 A1 EA 201992434A1 EA 201992434 A EA201992434 A EA 201992434A EA 201992434 A EA201992434 A EA 201992434A EA 201992434 A1 EA201992434 A1 EA 201992434A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sporozoites
seq
plasmodia
antibodies
new anti
Prior art date
Application number
EA201992434A
Other languages
English (en)
Inventor
Антонио Ланцавеккья
Джошуа Хун Юй Тань
Клаудия Даубенбергер
Брэндон Сэк
Original Assignee
Инститьют Фор Рисерч Ин Байомедисин
Сиэтл Чилдренс Хоспитл Ди/Би/Эй Сиэтл Чилдренс Рисерч Инститьют
Швайцеришес Тропен- Унд Паблик Хелс-Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инститьют Фор Рисерч Ин Байомедисин, Сиэтл Чилдренс Хоспитл Ди/Би/Эй Сиэтл Чилдренс Рисерч Инститьют, Швайцеришес Тропен- Унд Паблик Хелс-Институт filed Critical Инститьют Фор Рисерч Ин Байомедисин
Publication of EA201992434A1 publication Critical patent/EA201992434A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описан фрагмент циркумспорозоитного белка плазмодия, представленный в SEQ ID NO: 1, например, для применения в противомалярийной вакцине. В заявке описаны также нуклеиновые кислоты, кодирующие фрагмент циркумспорозоитного белка плазмодия, представленный в SEQ ID NO: 1, композиции, содержащие фрагмент циркумспорозоитного белка плазмодия, представленный в SEQ ID NO: 1, и антитела, которые связываются с фрагментом циркумспорозоитного белка плазмодия, представленным в SEQ ID NO: 1. Антитела, предлагаемые в настоящем изобретении, связываются специфически со спорозоитами P. falciparum и их можно применять для лечения и/или предупреждения малярии.
EA201992434A 2017-04-19 2018-04-19 Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия EA201992434A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487266P 2017-04-19 2017-04-19
PCT/EP2018/060113 WO2018193063A2 (en) 2017-04-19 2018-04-19 Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Publications (1)

Publication Number Publication Date
EA201992434A1 true EA201992434A1 (ru) 2020-03-30

Family

ID=62063036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992434A EA201992434A1 (ru) 2017-04-19 2018-04-19 Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия

Country Status (11)

Country Link
US (1) US20200093909A1 (ru)
EP (1) EP3612562A2 (ru)
JP (2) JP7278259B2 (ru)
KR (1) KR102595238B1 (ru)
CN (2) CN118085055A (ru)
AU (1) AU2018253918A1 (ru)
BR (1) BR112019021824A2 (ru)
CA (1) CA3058979A1 (ru)
EA (1) EA201992434A1 (ru)
SG (1) SG11201909265QA (ru)
WO (1) WO2018193063A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051642A1 (zh) * 2017-09-12 2019-03-21 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
WO2019195314A2 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
EP3962523A2 (en) * 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2021001351A1 (en) * 2019-07-01 2021-01-07 Deutsches Krebsforschungszentrum Plasmodium antibodies
US20220280632A1 (en) * 2019-07-24 2022-09-08 Bryce Chackerian Malaria immunogen and methods for using same
WO2021068080A1 (en) * 2019-10-09 2021-04-15 The Hospital For Sick Children Immunogenic peptides, compositions, and methods for the treatment and/or prevention of malaria
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
EP4192498A1 (en) * 2020-08-06 2023-06-14 Macfarlane Burnet Institute for Medical Research and Public Health Limited Immunogenic compositions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US20030119733A1 (en) * 1992-09-17 2003-06-26 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0729473T3 (da) 1993-11-17 2000-10-30 Deutsche Om Arzneimittel Gmbh Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6207242B1 (en) 1995-12-28 2001-03-27 Hoffman Environmental System, Inc. Laminated package with enhanced interior and exterior
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
CN1250548C (zh) 2001-04-17 2006-04-12 大日本住友制药株式会社 新的腺嘌呤衍生物
JP2005513021A (ja) 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP1641826A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN101190946A (zh) * 2006-12-01 2008-06-04 中国人民解放军第二军医大学 重组恶性疟原虫环子孢子表面蛋白及其制法和用途
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
US9347043B2 (en) 2008-10-22 2016-05-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
EP2624862A1 (en) * 2010-10-10 2013-08-14 Aduro Biotech Methods and compositions for inducing a t-cell response to plasmodium species
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition

Also Published As

Publication number Publication date
JP2023058633A (ja) 2023-04-25
WO2018193063A2 (en) 2018-10-25
CA3058979A1 (en) 2018-10-25
CN110945022A (zh) 2020-03-31
SG11201909265QA (en) 2019-11-28
BR112019021824A2 (pt) 2020-06-02
JP7278259B2 (ja) 2023-05-19
CN118085055A (zh) 2024-05-28
EP3612562A2 (en) 2020-02-26
KR20200141917A (ko) 2020-12-21
KR102595238B1 (ko) 2023-10-26
AU2018253918A1 (en) 2019-10-31
WO2018193063A3 (en) 2019-01-03
CN110945022B (zh) 2024-04-05
JP2020520674A (ja) 2020-07-16
US20200093909A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
EA201992434A1 (ru) Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
IL266222A (en) Messenger RNA acids for increasing immune responses and methods for their use
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
WO2015052543A3 (en) Malaria vaccination
MY187161A (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EA200900033A1 (ru) Вакцины против малярии
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201792328A1 (ru) Способ очистки белков
CY1124110T1 (el) Συνθεσεις και μεθοδοι μεταλλαγμενου παραγοντα viii
MY182046A (en) Interferon alpha and omega antibody antagonists
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
WO2015107363A3 (en) Mycobacterial antigen composition
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
WO2020227228A3 (en) Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
MX2018003103A (es) Composiciones y procedimientos contra la malaria.
MX2021013252A (es) Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.
IN2014DN09445A (ru)
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
NZ742663A (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
CO2018000255A2 (es) Polipéptido quimérico, vacuna contra la babesiosis, métodos de detección y kit